Abiopharma

🔍 Venker Eric (Executive)

Company: Roivant Sciences Ltd. (ROIV)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 200,000 shares of Common Shares at $3.85 per share (Direct)
  Date: 2026-03-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,847,546.00 | transaction_form_type: 4
• Sold 200,000 shares of Common Shares at $28.24 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,647,546.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200,000 shares of Stock Option (Right to Buy) at $3.85 per share (Derivative)
  Date: 2026-03-17 | Code: M | Expires: 2032-04-19 | equity_swap_involved: 0 | shares_owned_after: 4,844,834.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
• F2: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).